Article
Oncology
Wencheng Zhang, Cihui Yan, Tian Zhang, Xi Chen, Jie Dong, Jingjing Zhao, Dong Han, Jun Wang, Gang Zhao, Fuliang Cao, Dejun Zhou, Hongjing Jiang, Peng Tang, Lujun Zhao, Zhiyong Yuan, Quanren Wang, Ping Wang, Qingsong Pang
Summary: Combining concurrent chemoradiotherapy with the anti-PD-1 antibody camrelizumab as first-line treatment for locally advanced esophageal squamous cell carcinoma is safe and feasible, showing promising antitumour efficacy and manageable adverse effects. Biomarkers such as tumor PD-L1 expression and specific immune cells in peripheral blood were associated with overall survival, indicating the potential of this treatment strategy for further study.
Article
Oncology
Nai-Bin Chen, Qi-Wen Li, Su Li, Su-Ping Guo, Ying-Jia Wu, Zhangkai J. Cheng, Ji-Bin Li, Da-Quan Wang, Fang-Jie Liu, Xin-Lei Ai, Nan Hu, Bo Qiu, Hui Liu
Summary: This phase I trial aimed to determine the maximal tolerated dose of incorporating a twice-weekly docetaxel and nedaplatin regimen into definitive concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma patients. The study showed that the maximal tolerated dose was 5 mg/m2 and the low dose concurrent docetaxel and nedaplatin had promising radiosensitizing effect and good tolerability in the treatment of inoperable ESCC patients.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Satoru Matsuda, Tomoyuki Irino, Hirofumi Kawakubo, Masashi Takeuchi, Erika Nishimura, Kazuhiko Hisaoka, Junichi Sano, Ryota Kobayashi, Kazumasa Fukuda, Rieko Nakamura, Hiroya Takeuchi, Yuko Kitagawa
Summary: In this study, an AI-guided endoscopic response evaluation using a deep neural network was developed to discriminate endoscopic responders in patients with ESCC after NAC. The AI method showed high sensitivity, specificity, PPV, and NPV, suggesting its accuracy and feasibility.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Takahito Sugase, Keijiro Sugimura, Takashi Kanemura, Tomohira Takeoka, Masaaki Yamamoto, Naoki Shinno, Hisashi Hara, Takeshi Omori, Yoshiaki Fujii, Yosuke Mukai, Manabu Mikamori, Shinichiro Hasegawa, Naotsugu Haraguchi, Hirofumi Akita, Junichi Nishimura, Hiroshi Wada, Chu Matsuda, Masayoshi Yasui, Hiroshi Miyata
Summary: This study compared postoperative recurrence patterns and outcomes in patients with radical esophagectomy after preoperative CRT or DCF. The results showed that DCF patients had fewer distant recurrences, while CRT patients had better control of locoregional recurrence but higher risk of distant recurrence.
Review
Oncology
Ronald Chow, Kyle Murdy, Marcus Vaska, Sangjune Laurence Lee
Summary: Patients with esophageal carcinoma receiving neoadjuvant chemoradiotherapy and esophagectomy have better overall survival compared to those receiving definitive chemoradiotherapy. However, further studies are needed due to limited data and inconsistent reporting of endpoints.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Smita Sihag, Samuel C. Nussenzweig, Henry S. Walch, Meier Hsu, Kay See Tan, Sergio De La Torre, Yelena Y. Janjigian, Steven B. Maron, Geoffrey Y. Ku, Laura H. Tang, Pari M. Shah, Abraham Wu, David R. Jones, David B. Solit, Nikolaus Schultz, Karuna Ganesh, Michael F. Berger, Daniela Molena
Summary: MDM2 amplification and TP53 status are associated with response to therapy in patients with esophageal adenocarcinoma. Worsening TP53 dysfunction is directly correlated with worse treatment outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Surgery
Ryoma Haneda, Eisuke Booka, Kenjiro Ishii, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Kinji Kamiya, Hirofumi Ogawa, Hirofumi Yasui, Hiroya Takeuchi, Yasuhiro Tsubosa
Summary: Definitive chemoradiotherapy may be a promising alternative therapy comparable with radical esophagectomy in patients with clinical T1bN0M0 esophageal squamous cell carcinoma. Early detection of recurrence by frequent follow-up after definitive chemoradiotherapy is crucial for controlling disease within local recurrence, and salvage therapy for local lesions could contribute to long-term survival.
WORLD JOURNAL OF SURGERY
(2021)
Article
Oncology
Eisuke Booka, Ryoma Haneda, Kenjiro Ishii, Takahiro Tsushima, Hirofumi Yasui, Yasuhiro Tsubosa
Summary: The study found that preoperative chemotherapy was ineffective for elderly patients aged 75-80 with cStage 2 or 3 esophageal cancer and performance status (PS) 0, and significantly negatively impacted the overall survival (OS) of patients with PS 1. Therefore, it is recommended that preoperative chemotherapy should not be administered to patients 75 years of age or older with cStage 2 or 3 esophageal cancer.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Ken Sasaki, Yusuke Tsuruda, Masataka Shimonosono, Masahiro Noda, Yasuto Uchikado, Takaaki Arigami, Daisuke Matsushita, Shinichiro Mori, Akihiro Nakajo, Hiroshi Kurahara, Takao Ohtsuka
Summary: This study compared the efficacy of cisplatin and 5-fluorouracil (CF) with docetaxel and CF (DCF) in the treatment of locally advanced esophageal squamous cell carcinoma (ESCC). While both groups had similar rates of pathological complete response, the DCF group showed significantly better 5-year disease-free survival and 5-year overall survival compared to the CF group.
ANTICANCER RESEARCH
(2022)
Article
Oncology
Baoqing Chen, Meiling Deng, Chen Yang, Mihnea P. Dragomir, Lei Zhao, Kunhao Bai, Mian Xi, Yonghong Hu, Yujia Zhu, Qiaoqiao Li
Summary: This study retrospectively analyzed the outcomes of 136 patients with T4b esophageal squamous cell carcinoma treated with chemoradiotherapy. The incidence of esophageal fistula was found to be high, with ulcerative tumors and invasion of the bronchus/trachea posing a significantly higher risk for fistula formation.
RADIOTHERAPY AND ONCOLOGY
(2021)
Article
Oncology
Hui-Shan Chen, Ching-Hsiung Lin, Shiao-Chi Wu, Bing-Yen Wang
Summary: This study compared the survival outcomes of neoadjuvant chemoradiotherapy followed by operation, definitive chemoradiotherapy, and esophagectomy alone in patients with locoregional esophageal squamous cell carcinoma. It found that neoadjuvant chemoradiotherapy followed by operation and esophagectomy alone were associated with better overall survival compared to definitive chemoradiotherapy.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Maarten C. C. M. Hulshof, Elisabeth D. Geijsen, Tom Rozema, Vera Oppedijk, Jeroen Buijsen, Karen J. Neelis, Joost J. M. E. Nuyttens, Maurice J. C. van der Sangen, Paul M. Jeene, Jannie G. Reinders, Mark I. van Berge Henegouwen, Adriana Thano, Jeanin E. van Hooft, Hanneke W. M. van Laarhoven, Ate van der Gaast
Summary: In definitive chemoradiation for esophageal cancer, escalating radiation dose up to 61.6 Gy to the primary tumor did not significantly improve local tumor control compared to 50.4 Gy. The absence of a dose-effect was observed in both adenocarcinoma and squamous cell carcinoma.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Sehhoon Park, Dongryul Oh, Yoon-La Choi, Sang Ah Chi, Kyunga Kim, Myung-Ju Ahn, Jong-Mu Sun
Summary: Durvalumab and tremelimumab combined with definitive concurrent chemoradiotherapy showed promising efficacy in patients with locally advanced esophageal squamous cell carcinoma (ESCC), and PD-L1 expression had strong predictive value in predicting survival outcomes for these patients.
Article
Oncology
Xing Gao, Yu-Wen Wen, Joseph Jan Baptist van Lanschot, Yin-Kai Chao
Summary: This study investigated the cost-effectiveness of neoadjuvant therapy followed by surgery (NT) versus upfront surgery followed by adjuvant therapy (US) for patients with esophageal squamous cell carcinoma (ESCC). The results showed that NT is a preferable option for patients with clinical stage 3 ESCC due to its higher cost-effectiveness, while US remains a viable option for stage 2 disease.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Wing-Lok Chan, Cheuk-Wai Choi, Ian Yu-Hong Wong, Terence Hon-Ting Tsang, Adrian Tin-Chung Lam, Rosa Pui-Ying Tse, K. K. Chan, Claudia Wong, Betty Tze-Ting Law, Emina Edith Cheung, Siu-Yin Chan, Ka-On Lam, Dora Kwong, Simon Law
Summary: This study reviewed the long-term clinical outcomes and safety data of induction chemotherapy followed by surgery or definitive chemoradiotherapy in patients with locally advanced unresectable esophageal cancer. The results showed that patients who received subsequent surgery had significantly longer median overall survival compared to those who had definitive chemoradiotherapy or no definitive treatment. Induction chemotherapy followed by conversion surgery offered a chance of cure with long-term survival benefit and manageable toxicities in these patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)